RxDoctor Payments Data

Edwin Peguero-Rivera, MD

Neurology · Tampa, FLNPI 1972569291

Payments from drug & device makers

$1,012in general payments, 2019–2025

Across 19 payments — averaging $53.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$311
  • UCB, Inc.$208
  • Greenwich Biosciences, Inc.$127
  • Sunovion Pharmaceuticals Inc.$122
  • Argenx US, Inc.$121
  • AbbVie$106
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$92391%
  • Education$899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,012 in reported general payments places this provider in the 40th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$19,091
Medicare patients
187
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate23$39,082
BriviactBrivaracetam22$36,701
Lacosamide15$6,091
Levetiracetam ErLevetiracetam20$767
Levetiracetam20$701
Pregabalin16$620
Memantine Hcl20$474
Clonazepam17$349
Baclofen14$334
Gabapentin22$325
Divalproex Sodium14$261
Pentoxifylline11$233
Zonisamide20$201
Alprazolam16$199
Lamotrigine14$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$208$36,70122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,434 neurology providers in Florida.

Other neurology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →